Cambridge-based Sarepta Therapeutics said Tuesday that a patient died while taking its closely watched gene therapy for muscular dystrophy, sending company shares plummeting in morning trading.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback